10 minute read
May 11, 2023

ACT-777991: Next-Generation CXCR3 Antagonist in Phase I Trials for Type 1 Diabetes


oral reversible CXCR3 antagonist Ph. I in healthy subjects opt. of known CXCR3 antagonists J. Med. Chem., March 8, 2023 Idorsia Pharmaceuticals Ltd, CH


MOTY Nominees

Molecule of the Year